Summary
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
Official Title
AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients With Advanced Solid Tumors With AKT1 E17K Mutation
Details
This is an open-label, multicenter, Phase 1/1b study of ALTA2618, a mutant-selective and orally bioavailable AKT1 E17K inhibitor, in adults with AKT1 E17K-mutant solid tumors. This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity of ALTA2618, and aims to find the best dose. The study consists of two parts: Part 1 - Dose Escalation and Part 1b - Dose Expansion.
Keywords
Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor, AKT1 E17K, Breast carcinoma, Breast neoplasm, ER positive breast, HR positive breast, Triple negative breast cancer, Gynecologic cancer, Gynecologic neoplasm, Gynecologic carcinoma, Endometrial neoplasm, Endometrial carcinoma, Cervical cancer, Cervical neoplasm, Cervical carcinoma, Ovarian cancer, Ovarian carcinoma, Ovarian neoplasm, Fallopian cancer, Fallopian carcinoma, Fallopian neoplasm, Prostate cancer, Prostate carcinoma, Prostate neoplasm, Solid tumors, AKT mutation, Mutant AKT, AKT1 mutation, AKT mutant, AKT1E17K, Breast Neoplasms, Endometrial Neoplasms, ALTA2618
